Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.01 -2.0%	$1.99	$1.60 ▼ $2.54	$775.22M	1.03	1.37 million shs	1.78 million shs
REPL Replimune Group	$12.09 -3.3%	$9.53	$6.44 ▼ $17.00	$931.98M	0.61	947,958 shs	3.35 million shs
TIL Instil Bio	$26.10 -5.8%	$25.64	$9.85 ▼ $92.00	$171.19M	2.15	199,165 shs	159,263 shs
VIR Vir Biotechnology	$5.41 -1.5%	$5.14	$4.32 ▼ $14.45	$747.87M	1.22	1.37 million shs	2.07 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	-1.95%	-3.83%	+5.24%	+13.56%	-17.96%
REPL Replimune Group	-3.28%	+10.21%	+27.40%	+51.31%	+13.73%
TIL Instil Bio	-5.78%	+6.57%	-8.68%	+68.93%	+100.77%
VIR Vir Biotechnology	-1.46%	-4.25%	+3.84%	-1.64%	-47.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.0584 of 5 stars	0.0	4.0	0.0	2.6	0.0	2.5
REPL Replimune Group	4.1214 of 5 stars	3.6	1.0	4.5	2.5	2.5	0.6
TIL Instil Bio	2.4243 of 5 stars	3.5	2.0	0.0	0.6	3.3	0.6
VIR Vir Biotechnology	3.5846 of 5 stars	3.4	4.0	0.0	2.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
REPL Replimune Group	3.13	Buy	$21.00	73.70% Upside
TIL Instil Bio	3.00	Buy	$119.00	355.94% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	459.15% Upside

Current Analyst Ratings Breakdown

Latest TIL, VIR, CRON, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$16.00 ➝ $19.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.59	$0.00 per share	4,319.61	$2.90 per share	0.69
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A
VIR Vir Biotechnology	$74.21M	10.08	N/A	N/A	$8.35 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	15.46	67.00	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest TIL, VIR, CRON, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRON Cronos Group	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q1 2026	REPL Replimune Group	-$0.85	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	TIL Instil Bio	-$1.72	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	N/A	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
REPL Replimune Group	0.17	7.95	7.95
TIL Instil Bio	0.58	30.33	30.33
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
REPL Replimune Group	92.53%
TIL Instil Bio	60.56%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
REPL Replimune Group	8.80%
TIL Instil Bio	47.20%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

TIL, VIR, CRON, and REPL Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in Stock

July 18 at 10:14 PM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in Stock

July 18 at 10:14 PM | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of Stock

July 18 at 10:11 AM | insidertrades.com

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025 | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Raymond James Financial

July 13, 2025 | americanbankingnews.com

Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation

July 12, 2025 | msn.com

Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

July 10, 2025 | zacks.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $32.86 Consensus Price Target from Brokerages

July 10, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?

July 9, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

July 3, 2025 | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

July 2, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of Revenue

June 30, 2025 | marketbeat.com

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25, 2025 | finance.yahoo.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Tech Stocks Poised for Explosive EPS Growth in 2025
By Gabriel Osorio-Mazilli | July 8, 2025
View 3 Tech Stocks Poised for Explosive EPS Growth in 2025
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Micron Insiders Sell But Investors Should Buy, Buy, Buy
By Thomas Hughes | July 7, 2025
View Micron Insiders Sell But Investors Should Buy, Buy, Buy
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
3 Stocks to Cushion Your Portfolio This Earnings Season
By Chris Markoch | July 16, 2025
View 3 Stocks to Cushion Your Portfolio This Earnings Season

TIL, VIR, CRON, and REPL Company Descriptions

Cronos Group NASDAQ:CRON

$2.01 -0.04 (-1.95%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.00 -0.01 (-0.75%)

As of 07/18/2025 07:59 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Replimune Group NASDAQ:REPL

$12.09 -0.41 (-3.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$12.23 +0.14 (+1.16%)

As of 07/18/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Instil Bio NASDAQ:TIL

$26.10 -1.60 (-5.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.78 +0.67 (+2.59%)

As of 07/18/2025 05:56 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Vir Biotechnology NASDAQ:VIR

$5.41 -0.08 (-1.46%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.41 0.00 (0.00%)

As of 07/18/2025 06:39 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time